help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 9, 988-991, October 2006; doi:10.1634/theoncologist.11-9-988
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Genomics and the Impact of New Technologies on the Management of Colorectal...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harkin, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harkin, D. P.

Special Section on Colorectal Cancer

Genomics and the Impact of New Technologies on the Management of Colorectal Cancer

D. Paul Harkin

Queen’s University, Belfast, Northern Ireland, United Kingdom, and ArraDx Ltd, Craigavon, Northern Ireland, United Kingdom

Key Words. Genomics • Array-based comparative genomic hybridization • Single-nucleotide polymorphism arrays • Microarrays • RNA Later • Formalin-fixed paraffin-embedded

Correspondence: D. Paul Harkin, Ph.D., Chief Executive Officer, ArraDx Ltd, Marty Murphy Building, 19 Seagoe Industrial Estate, Craigavon, Co. Armagh BT63 5QD, Northern Ireland, UK. Telephone: +44 (0) 28 3833 7575; Fax: +44 (0) 28 3839 8676; e-mail: paul.harkin{at}arradx-almac.com

High-throughput genomic technologies have the potential to have a major impact on preclinical and clinical drug development and the selection and stratification of patients in clinical trials. These technologies, which are at varying stages of commercialization, include array-based comparative genomic hybridization, single-nucleotide polymorphism arrays, and (the most mature example) expression-based arrays. One of the rate-limiting steps in the routine clinical application of expression array-based technology is the need for suitable clinical samples. One of the major challenges moving forward, therefore, relates to the ability to use formalin-fixed, paraffin-embedded–derived tissue in expression profiling-based approaches.




This article has been cited by other articles:


Home page
 The OncologistHome page
P. G. Johnston
The Colorectal Cancer Coalition: Reflections on the Future
Oncologist, October 1, 2006; 11(9): 970 - 972.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2006 by AlphaMed Press.